{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:27:55Z","timestamp":1771954075397,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Twice\u2010weekly carfilzomib with lenalidomide\u2010dexamethasone (Rd) is an effective regimen for newly diagnosed multiple myeloma (NDMM). Here we evaluated once\u2010weekly carfilzomib with Rd (once\u2010weekly KRd) in NDMM patients. The NDMM patients were enrolled regardless of transplant eligibility. Patients received carfilzomib on days 1, 8, and 15; lenalidomide 25\u2009mg on days 1\u201021; and dexamethasone 40\u2009mg on carfilzomib days (also day 22 for cycles 1\u20108) for \u226418, 28\u2010day\u2009cycles. Enrollment initiated in a carfilzomib 20\/70\u2009mg\/m<jats:sup>2<\/jats:sup> (20\u2009mg\/m<jats:sup>2<\/jats:sup> on cycle one, day 1; 70\u2009mg\/m<jats:sup>2<\/jats:sup> thereafter) NDMM dose\u2010expansion arm, which was suspended because of serious adverse events. After evaluation of dose\u2010limiting toxicities in a two\u2010step\u2010up dose\u2010evaluation cohort, an NDMM dose\u2010expansion arm (carfilzomib 20\/56\u2009mg\/m<jats:sup>2<\/jats:sup>) was opened. Fifty\u2010one NDMM patients were enrolled in dose\u2010finding and dose\u2010expansion cohorts. Results are presented for the carfilzomib 56\u2009mg\/m<jats:sup>2<\/jats:sup> NDMM dose\u2010expansion arm (n = 33). The grade\u2009\u2265\u20093 treatment\u2010emergent AE (TEAE) rate was 63.6%. Twenty\u2010five patients underwent stem cell collection; 18 proceeded to auto stem cell transplant, and five resumed KRd on study after autoSCT. The overall response rate (ORR) based on best overall response by cycle four was 97.0% (\u2265very good partial response [VGPR], 69.7%) in the NDMM 20\/56\u2009mg\/m<jats:sup>2<\/jats:sup> cohort. In patients who did not receive autoSCT (n = 15), the median number of cycles was 16.0; ORR was 93.3% (\u2265VGPR, 80.0%). At a median follow\u2010up of 8.1 months, median progression\u2010free survival was not reached. Once\u2010weekly KRd (carfilzomib 56\u2009mg\/m<jats:sup>2<\/jats:sup>) had a favorable safety profile and promising activity in NDMM, supporting the use of this regimen in this setting.<\/jats:p>","DOI":"10.1002\/ajh.26041","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T19:39:18Z","timestamp":1604086758000},"page":"226-233","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase 1b study of once\u2010weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma"],"prefix":"10.1002","volume":"96","author":[{"given":"Melissa","family":"Alsina","sequence":"first","affiliation":[{"name":"Moffit Cancer Center  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine New York Presbyterian Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William I.","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah School of Medicine  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center  Hackensack New Jersey USA"},{"name":"Medstar Georgetown University Hospital  Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belle","family":"Fang","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Kimball","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center  Hackensack New Jersey USA"},{"name":"Medstar Georgetown University Hospital  Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"issue":"1","key":"e_1_2_9_5_1","first-page":"4533","article-title":"High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial","volume":"130","author":"Jakubowiak AJ","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2010"},{"key":"e_1_2_9_7_1","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma. Version 3.2020.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed April 17 2020."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"issue":"1","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","article-title":"Carfilzomib\u2010lenalidomide\u2010dexamethasone (KRd) Induction\u2010autologous transplant (ASCT)\u2010Krd consolidation vs KRd 12 cycles vs carfilzomib\u2010cyclophosphamide\u2010dexamethasone (KCd) induction\u2010ASCT\u2010KCd consolidation: analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM)","volume":"132","author":"Gay F","year":"2018","journal-title":"Blood"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5457"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0384-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15394"},{"issue":"22","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V128.22.674.674","article-title":"Ixazomib\u2010lenalidomide\u2010dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du My\u00e9Lome (IFM)","volume":"128","author":"Moreau P","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0480-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25498"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"issue":"22","key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V128.22.1142.1142","article-title":"Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du My\u00e9Lome (IFM) Krd phase II study","volume":"128","author":"Roussel M","year":"2016","journal-title":"Blood"},{"issue":"10","key":"e_1_2_9_28_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem\u2010cell transplantation (ENDURANCE): a multicentre, open\u2010label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar S","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26041","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T08:19:26Z","timestamp":1693124366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/ajh.26041"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26041","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"assertion":[{"value":"2020-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}